Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.37)
# 399
Out of 5,112 analysts
84
Total ratings
55.74%
Success rate
18.75%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $21.58 | +85.36% | 2 | Dec 16, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $36.78 | +49.54% | 1 | Nov 26, 2025 | |
| BEAM Beam Therapeutics | Initiates: Outperform | $35 | $26.98 | +29.73% | 1 | Nov 24, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Outperform | $25 | $8.16 | +206.37% | 1 | Nov 20, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $40 | $29.93 | +33.65% | 1 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $62.79 | +27.41% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $5.88 | +104.08% | 1 | Sep 3, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $17.58 | +93.40% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $44.19 | +24.46% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $33.86 | -5.49% | 6 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $144.87 | +27.70% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $75.23 | -33.54% | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $24.34 | +105.42% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $92.79 | +34.71% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $61.69 | +70.21% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,250 → $1,175 | $764.94 | +53.61% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $64.96 | +30.85% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $33.80 | +160.36% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $174.41 | +58.25% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $4.49 | +679.51% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $328.78 | -29.44% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $101.47 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $125.38 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $28.43 | -26.13% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $5.64 | +307.80% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $10.98 | +2,177.90% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.12 | +792.86% | 1 | Feb 14, 2018 |
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $21.58
Upside: +85.36%
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $36.78
Upside: +49.54%
Beam Therapeutics
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $26.98
Upside: +29.73%
ORIC Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $8.16
Upside: +206.37%
Upstream Bio
Nov 18, 2025
Initiates: Outperform
Price Target: $40
Current: $29.93
Upside: +33.65%
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $62.79
Upside: +27.41%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $5.88
Upside: +104.08%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $17.58
Upside: +93.40%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $44.19
Upside: +24.46%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $33.86
Upside: -5.49%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $144.87
Upside: +27.70%
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $75.23
Upside: -33.54%
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $24.34
Upside: +105.42%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $92.79
Upside: +34.71%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $61.69
Upside: +70.21%
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $764.94
Upside: +53.61%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $64.96
Upside: +30.85%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $33.80
Upside: +160.36%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $174.41
Upside: +58.25%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $4.49
Upside: +679.51%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $328.78
Upside: -29.44%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $101.47
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $125.38
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $28.43
Upside: -26.13%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $5.64
Upside: +307.80%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $10.98
Upside: +2,177.90%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.12
Upside: +792.86%